Surveillance for Antiviral-Agent-Resistant Herpes Simplex Virus in the General Population with Recurrent Herpes Labialis

Abstract

In a general population survey in the United States, the prevalence of antiviral-agent-resistant herpes simplex virus was very low among more than 1,000 isolates from individuals with an episode of recurrent herpes labialis not treated with topical antiviral agents. Two isolates had borderline resistance to acyclovir (0.2%), and all were susceptible to penciclovir.

Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management

“…A low prevalence of HSV resistance to ACV was reported in immunocompetent patients during extensive screening surveys in the United Kingdom (0.7%) and the United States (0.3%) between 1980 and 1992 (59). Most studies since then did not report an increase in the prevalence of resistance (ranging from 0.1 to 0.7%) (7,9,33,51,68,171,212). In general, in this population, drug resistance was not associated with an adverse clinical outcome, due to immune competence.…”

Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy

“…Furthermore, there has been no detectable change over time in this prevalence based on data for isolates collected during clinical trials, from patients who had not responded well to acyclovir, and from population-based surveys (Table 3), (2,8,14,17; Reyes et al, Abstr. 11th Int.…”

“…Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for over two decades, but isolation of drug-resistant HSV from immunocompetent patients remains infrequent (0.1 to 0.7% with a mean of 0.3% [2,8,14,17; M. J. Reyes, J. M. Graber, N.…”

In vitro Broad Antiviral Function against HBV, HSV, H3N2 Replication by Baicalin and Oroxylin A-7-O-Β-D-Glucoside

“…HSV-2 infection can be treated with NAs such as acyclovir, but frequent NA use can cause relatively high toxicity and emergence of drug-resistant HSV strains especially in immunocompromised patients [6]. Influenza A virus (IAV) is a common human pathogen, and can cause epidemics of severe respiratory illness, causing significant mortality and economic loss [7,8].…”